LeMaitre VascularLMAT
About: LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
Employees: 630
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
142% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 19
80% more call options, than puts
Call options by funds: $483K | Put options by funds: $269K
13% more capital invested
Capital invested by funds: $1.72B [Q2] → $1.94B (+$223M) [Q3]
10% more funds holding
Funds holding: 261 [Q2] → 288 (+27) [Q3]
8% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 95
0% less ownership
Funds ownership: 92.93% [Q2] → 92.92% (-0%) [Q3]
20% less funds holding in top 10
Funds holding in top 10: 5 [Q2] → 4 (-1) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Oppenheimer Suraj Kalia 36% 1-year accuracy 8 / 22 met price target | 1%upside $93 | Outperform Reiterated | 1 Nov 2024 |
Barrington Research Michael Petusky 43% 1-year accuracy 29 / 68 met price target | 1%upside $93 | Outperform Maintained | 1 Nov 2024 |
Cantor Fitzgerald Ross Osborn 49% 1-year accuracy 23 / 47 met price target | 4%upside $96 | Neutral Initiated | 15 Oct 2024 |
Financial journalist opinion
Based on 4 articles about LMAT published over the past 30 days
